Pathway Genomics

Pathway Genomics Corporation
Private
Industry Biotechnology
Founded 2008 (2008)
Founder James Plante
Headquarters San Diego, California, United States
Website www.pathway.com

Pathway Genomics is a privately held global precision medical diagnostic company with mobile applications designed to empower physicians and their patients to take control of their health and wellness. Based in San Diego, California, the company offers genetic testing to physicians for their patients to support treatment a variety of health conditions. The test menu ranges from somatic and hereditary cancer, including BRCA1 and BRCA2, to pharmacogenomics testing for well-known drugs like Plavix, codeine, lamotrigine, to general health and wellness testing which includes information on a number of health conditions including type 1 and type 2 diabetes and hypertension.

Pathway Genomics owns and operates a clinical laboratory accredited by the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA)[1] which “provides physicians and their patients with actionable and accurate precision healthcare information to improve or maintain, health and wellness in more than 40 different countries.”[2]

History

The company was founded with the vision to make “genetic testing and personalized medicine accessible and affordable to everyone.”[3] Pathway Genomics’ testing services cover a variety of conditions including somatic & hereditary cancer risk, cardiac health, inherited diseases, nutrition and exercise response, as well as drug response.[4]

In addition to continual testing improvements and new testing developments, Pathway Genomics is also currently developing OME™. OME is the “world’s only mobile healthcare consumer application with artificial intelligence to help provide consumers with personalized health and wellness information.[5]

IBM Partnership

In 2014, IBM Watson Group announced its partnership with Pathway Genomics, to help “deliver the first-ever cognitive consumer-facing app based on genetics from a user’s personal makeup.”[6] The mobile app, subsequently named OME, is the first of its kind to merge artificial intelligence and deep learning, powered by IBM Watson, with personal genetic information. It provides users with personalized health and wellness information based on the individual’s health history.[7]

Products

General Health & Wellness
Tests in this category analyze a variety of genomic markers selected to give patients and providers a better understanding of a patient’s risk for a number of health conditions. These tests help individuals to better understand their genetic propensity to specific diets, eating behaviors, nutritional needs, exercise activity and various health conditions, which is important for true, long-term, overall health and success in weight management.[8]


Pharmacogenomics
Pharmacogenomic testing provides physicians with information about how their patient’s body responds to commonly prescribed pain, mental health, and cardiac-related medications.[9]


Liquid Biopsy
The CancerIntercept™ tests are 96-mutation panels designed for the detection of somatic mutations in a set of 9 driver genes involved primarily in breast, ovarian, lung, and colorectal cancers, and melanoma. These tests, which must be ordered by a physician, may be used to either monitor patients already diagnosed with cancer or potentially detect undiagnosed cancer. Results are available within 2–3 weeks.[10]


Hereditary Cancer Tests
Hereditary cancer testing is offered to patients with a personal and/or family history suggestive of cancer. These testing options include targeted panels, full gene panels, and a number of reflexive testing options.[11]


Carrier Screening
Carrier DNA Insight® is a comprehensive preconception and prenatal carrier screening test. Carrier DNA Insight® follows the American College of Obstetricians and Gynecologists (ACOG) recommendations, and screen patients for more than 70 recessive genetic diseases. Carrier DNA Insight® provides physicians with information about the risks of inherited diseases of their patients’ future childrens.[12]


Executives

Pathway Genomics’ executives include James Plante (Founder and CEO), Kamal Adawi (Chief Financial Officer), Michael Nova, M.D. (Chief Innovation Officer), K’Lene Oen (Chief Business Officer), Anthony Facinelli (Executive Vice President, Domestic Sales, Anja Kammesheidt, Ph.D. (Chief Scientific Officer), Nilesh Dharajiya, M.D. (Chief Laboratory Officer & Medical Director), Glenn D. Braunstein, M.D. (Chief Medical Officer), Michael H. Cox, CIPP (Chief Privacy and Compliance Officer), and Mitch Mulanix (Vice President of Business Development and Government Relations).[13]

Board of Directors

Pathway Genomics’ Board of Directors include the sixteenth Chairman of the Joint Chiefs of Staff, retired U.S. Marine General Peter Pace, Mark W. Sopp, Chris Kitching, and James Plante.[14]

See also

Single-nucleotide polymorphism (SNP)
Pharmacogenomics
Genetic counseling
Genomic counseling

References

  1. ↑ "." Licenses/Accreditations. Retrieved 1 August 2015.
  2. ↑ "." Press releases. Retrieved 1 September 2015.
  3. ↑ "." James Plante, Founder and CEO. Retrieved 12 July 2015.
  4. ↑ "." Our tests. Retrieved 7 July 2015.
  5. ↑ "." OME™ Cognitive Mobile Health & Wellness. Retrieved 8 August 2015.
  6. ↑ "." IBM Watson Group Invests in Pathway Genomics to Help Personalize Consumer Health. Press Release; IBM. 12 Nov 2014. Retrieved 24 June 2015.
  7. ↑ "." OME™ Cognitive Mobile Health & Wellness. Retrieved 8 August 2015.
  8. ↑ "." DNA Insight™ General Health & Wellness Genetics Tests. Retrieved 5 March 2015.
  9. ↑ "." DNA Insight™ Pharmacogenomics Tests. Retrieved 1 June 2015.
  10. ↑ "." Pathway Genomics – Liquid Biopsy CancerIntercept™. Retrieved 10 September 2015.
  11. ↑ "." True™ Hereditary Cancer Tests. Retrieved 1 August 2015.
  12. ↑ "." Carrier Screening. Retrieved 16 May 2016.
  13. ↑ "." Management Team. Retrieved 16 May 2016.
  14. ↑ "." Board of Directors. Retrieved 16 May 2016.
This article is issued from Wikipedia - version of the 10/10/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.